Featured Stocks

Standard Lithium Ltd. (TSXV: SLL) (FRA: S5L) (OTCQX: STLHF)

Standard Lithium Ltd. is a Canadian-based energy exploration and development company that is building one of the largest portfolios of high quality, domestic U.S. lithium brine assets. Its data and technology driven project development model is grounded in knowledge, opportunity and speed. Standard Lithium is led by an innovative and results-oriented management team with a strong focus on technical skills. The company has acquired several prospective lithium brine projects with known geological values consistent with producing basins, including its primary focus, the Bristol Dry Lake, California brownfield project that is permitted for related mineral production with accompanying world class infrastructure which are expected to contribute to faster, lower cost exploration and commercial development programs.

Recent results from a geophysical survey of the 25,000-acre Bristol Lake site suggest a high concentration of lithium-bearing brines are present throughout the company’s mineral lease agreement claims. Standard Lithium’s strategic partner in the venture, National Chloride Corporation of America, is well established in the region. All necessary infrastructure is on site, which gives Standard Lithium immediate access to conduct exploration brine sampling, lithium extraction, evaporation and processing activities, all within a fast-track project development schedule.

World demand for lithium continues to surge. The global lithium compounds market is projected to reach U.S. $5.87 billion by 2020, at a compound annual growth rate of 13.22% between 2015 and 2020. Lithium-ion batteries are the fastest growing segment of the market.

Standard Lithium’s determination to provide battery-grade lithium materials is bolstered by its recently appointed Scientific Advisory Council. These leading lithium extraction scientists and process engineers will oversee and direct the necessary lithium extraction process testing work. In addition to the Bristol Lake Brine Project, the company signed a Memorandum of Understanding in August with an unnamed New York Stock Exchange-listed company on an option for Standard to acquire lithium exploration and productions rights on 30,000 net brine acres overlying the Smackover formation in a region with a history of commercial-scale brine processing. Management believes lithium-bearing brines are likely present in this area. Smackover brines are metal-rich brine anomalies in reservoir rocks along the Gulf Coast from east Texas to Florida known to be a prime lithium resource. This resource may be one of the most promising ones to develop, given that a large-scale brine extraction, processing and reinjection industry is already well established.

Recently, Standard Lithium closed a multi-million dollar private placement offering, which allows the company to advance its current projects and pursue strategic acquisitions in the lithium sector. The company is well positioned with significant exploration opportunities featuring low cost production costs, easy transport, proximity to demand, and access to innovative production methodology.

Investment Considerations

  • Exploration of Bristol Lake Project reveals excellent lithium-bearing brine harvest potential
  • Global lithium compounds market projected to reach U.S. $5.87 billion by 2020
  • Technological advances provide access to low cost, battery-grade lithium materials
  • World demand for lithium expected to increase 300% by 2025


Tuesday, October 3rd, 2017 Featured Stocks Comments Off

Pressure BioSciences Inc. (PBIO)

Pressure BioSciences, Inc. develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions – all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

Investment Considerations

  • Poised to disrupt sciences sample preparation market estimated at $6 billion
  • Nearly 300 patented enabling technology platform products installed at more than 150 sites worldwide
  • Two patents awarded in China for Ultra Shear Technology used in wide range of industrial applications, including “clean foods.”
  • Finalist in prestigious 2017 R&D 100 Awards recognizing top revolutionary technologies.
  • Technology being used as part of the U.S. “Cancer Moonshot” initiative.


Monday, October 2nd, 2017 Featured Stocks Comments Off

Moxian, Inc. (NASDAQ: MOXC)

Moxian, Inc. is a leading offline-to-online (O2O) integrated platform operator committed to providing high-quality social marketing and promotion platforms to end-users and merchants interested in promoting their business via social media.

The company’s proprietary Social Customer Relationship Management (Social CRM) system is at the foundation of its multi-channel social commerce platform, and was developed to foster enhanced consumer/merchant interaction. By integrating social media, entertainment and business intelligence, Moxian’s system is especially suitable for SMB, integrated entertainment, commerce, shopping and customer loyalty rewards providers.

Through its big data analytics system, Moxian has a clear picture of its targeted customers, their demands and payment data. End-user data generated from the platform helps Moxian’s merchant clients achieve optimal marketing strategies.

Leveraging these assets, Moxian has two primary core products: Moxian User App and Moxian Business App.

The structure of Moxian User APP is for consumers to collect loyalty points from issuing merchants. Virtual currency (MO-Coin and MO-Points) is earned playing games and can be redeemed globally with any merchant in Moxian eco-system. This model drives registered consumers to Moxian and its merchant clients while providing merchants the opportunity to advertise, run marketing campaigns, and learn about their customers through Moxian’s platform. The app also provides consumers a set of social networking features to set up a personalized multimedia profile and participate in traditional social media functions such as friend search, interest groups, topics and content sharing.

Moxian Business App is similar in that it is also based on loyalty points, but is geared toward the merchant. This app provides merchants the tool kits to covert customers into members and fans, issue loyalty points and redeem rewards, and respond to customer inquiries via instant messaging. Users can also conduct targeted marketing campaigns to members of Moxian community in the form of ads and games, list products online, as well as process orders. Moxian Business also provides business reports and analytical insights for merchants.

Led by a management team with more than a century of combined experience, Moxian’s technologies supplement the company’s broader corporate mission to create and lead a personalized social network platform best suited for modern users and businesses.

Investment Considerations

  • Proprietary technology is transforming today’s mobile, online and offline commerce capabilities
  • Social media marketing and promotion platforms help merchants accelerate and advertise business growth
  • Management team has 100+ years of combined experience in relevant technology, payment processing, finance and marketing
  • Board of experienced directors supplements management team, providing additional momentum to corporate initiatives

 


Friday, June 23rd, 2017 Featured Stocks Comments Off

India Globalization Capital, Inc. (IGC)

India Globalization Capital, Inc. (NYSE MKT: IGC) is a first mover in developing a portfolio of products using cannabis-based “combination therapies” for the treatment of Alzheimer’s, cachexia, pain and other conditions.

Through a definitive agreement with the University of South Florida, IGC is the exclusive licensee of the U.S. patent filing entitled “THC as a Potential Therapeutic Agent for Alzheimer’s Disease.” Known as America’s most expensive disease with an estimated cost to the U.S. economy of $236 billion, Alzheimer’s currently effects more than 5.3 million Americans and over the next 20 years the number of those afflicted with the disease is expected to double. By acquiring the exclusive right to this patent filing, IGC is protecting a potential cannabis-based blockbuster treatment.

The Company has also filed combination therapy formulations for the treatment of epilepsy and cachexia. About 50 million people worldwide are affected by epilepsy and about 1.3 million in the U.S. experience cachexia associated with cancer, MS, Parkinson’s, HIV/AIDS and other progressive illnesses. Cancer-induced anorexia/cachexia is responsible for 20% of all cancer deaths. IGC-502 indicated for seizures and IGC-504 indicated for cachexia are unique combination therapies that, if proven out by clinical trials, are expected to treat medical refractory epilepsy and eating disorders respectively, with lower side effects than conventional mono therapies.

Successful treatment of pain represents an enormous market opportunity as well with the national cost of health care due to pain ranging from $560 billion to $635 billion. In addition, the health care cost attributed to the abuse of prescription opioids, closely related to pain, is approximately $25 billion. IGC’s patent filing (IGC-501) is a cannabis-based formulation addressing neuropathic and arthritic pain in joints and muscles using a variety of delivery techniques. The Company anticipates commencing clinical trials, and hopes that through its focus on combination therapy it can formulate and commercialize cannabinoid compounds as an alternative to long-term addictive opioid treatments.

IGC’s strategy is exciting and unique in that it is aiming to become a leader in the phytocannabinoid-based combination therapy specialty pharmaceutical sector. This first mover advantage can potentially be formidable as it begins clinical trials and further builds its patent portfolio. “The development of combination therapies utilizing cannabis represents a large, unique opportunity in this emerging specialty-pharmaceutical sector. Securing FDA approval for combination therapy is believed to be significantly faster and less expensive than new drug applications. As a result, we believe that we can bring our cannabis-based pharmaceutical products to market in both an expeditious and cost-effective manner,” stated Ram Mukunda, CEO.

IGC has recently exited its legacy businesses. An impressive and experienced team, led by Mr. Ram Mukunda, CEO, directs IGC.

Mr. Mukunda holds degrees in Electrical Engineering and Mathematics from the University of Maryland (UMD). He founded and served as Chairman and CEO of Startec Global Communications, an international telecommunications carrier focused on providing voice over Internet protocol (VOIP) services to emerging economies. Startec, the first pure play international long distance carrier, went public on NASDAQ. He has won a number of awards, including the 2013 University of Maryland International Alumnus of the year award. Mr. Mukunda serves as an Emeritus member on the Board of Visitors at the University of Maryland, School of Engineering, and has served as Council Member at Harvard’s Kennedy School of Government, Belfer Center of Science and International Affairs. Mr. Mukunda and Dr. Krishna are the originators of all the IGC patent filings.

Dr. Ranga Krishna, Senior Advisor, is a Board Certified Neurologist with a sub specialty in Epilepsy surgery. He is the Director of Neurology at the New York Community Hospital affiliated with New York Presbyterian Weil Cornell Medical College and the Director of Stroke Service at the New York Community Hospital affiliated with New York Presbyterian Weil Cornell Medical College. He is the Medical Director and Chairman of Total Neuro Care, P.C. He is CEO of International Pharma Trials, Inc., which assists U.S. pharmaceutical companies perform Phase II clinical trials. Dr. Krishna is a member of several organizations, including the American Academy of Neurology and the Medical Society of the State of New York. He is also a member of the Medical Arbitration panel for the New York State Workers’ Compensation Board and a Founding Member of the New York State Pain Society. Dr. Krishna was trained at New York’s Mount Sinai Medical Center (1991-1994) and New York University (1994-1996). Dr. Krishna and Mr. Mukunda are the originators of all the IGC patent filings.

Investment Considerations

  • A ground floor opportunity in the medical cannabis specialty pharma space
  • Building a patented portfolio of phytocannabinoid-based pharmaceutical and nutraceutical products for Alzheimer’s, cachexia, Parkinson’s, and other diseases
  • Positioning for first-mover advantage in phytocannabinoid based combination therapy
  • First to run phytocannabinoid trials for decreasing amloyd beta in Alzheimer’s patients

 


Monday, May 8th, 2017 Featured Stocks Comments Off

Emblem Corp. (TSX.V: EMC) (OTC: EMMBF)

Emblem Corp. is a publicly traded, fully integrated Canadian medical and adult recreational cannabis company led by a team of proven senior executives with experience in the pharmaceutical industry, the cannabis horticulture industry and health care.

Emblem is an “indoor” cannabis producer, growing in six controlled environment indoor grow rooms at its facility in Paris, Ontario. A seventh grow room will be added by spring 2018, which will bring Emblem’s total capacity to 2,400 kilograms per year at a cost-effective 1.5 grams per watt.

Emblem is licensed by Health Canada to produce cannabis oils using super critical CO2 extraction technology. The company is currently completing an expansion that will provide about 30,000 square feet to house a GMP extraction laboratory, pharmaceutical production and value-added product facility. In preparation for the Canadian adult recreational cannabis market expected to rollout by July 2018, Emblem is planning to build a 115,000 square foot facility with an indoor capacity of 15,000 kilograms at 1.5 grams per watt.

Emblem has adopted a three-part strategy to the Canadian cannabis industry:

  • Targeting medical cannabis by focusing on the development and sale of cannabinoid-based pharmaceutical formulations; Emblem expects that more advanced cannabis formulations will displace dried flower and simple oils in the Canadian medical market.
  • Targeting the adult recreational cannabis market by distinguishing its product offerings through growing high quality indoor dried flowers and developing unique value-added, extraction-based products.
  • Targeting education and healthcare by providing medical cannabis patients with information and resources not generally available from the Canadian healthcare system.

The likely addition of cannabis-infused edibles and other concentrates to Canada’s legalization plans for marijuana are expected to produce significant revenue streams for the company. An amendment to Bill C-45, otherwise known as the Canadian Cannabis Act, would ensure these derivatives of cannabis will be available no later than 12 months after the country officially legalizes recreational cannabis in July 2018.

Emblem has invested several million dollars into its Pharma division to research marijuana drug candidates and potential new drugs derived from cannabis. Over time, the company expects this division to be the largest and most profitable as it focuses initially on bringing drugs to market that will address neuropathic pain, anxiety and sleep issues. By providing standardized, consistent doses of cannabinoid-based pills and oils, Emblem intends to lead the industry. Value-added products such as sustained release and accelerated release formulations will materially increase product demand. Emblem’s focus on regulating the growth environment by using a holistic, organic method means each cannabis strain is healthy and true to its mother plant, which in turn assures a naturally grown, robust medical cannabis product.

Emblem, which had 2,154 active patients as of August 2017, continues to enroll patients in its GrowWise Health program which is also seeing a marked expansion of its clinic network. Projected growth in this sector, along with the value-added benefits provided for patients and physicians, is expected to ensure ongoing patient registration. Emblem plans to open additional GrowWise Health clinic locations across Canada.

Covering the full cannabis spectrum, Emblem’s business is structured to reach new heights from growing to selling recreational and medical cannabis, to educating and assisting patients, to creating new forms of cannabinoid-based medications in standardized, high quality and convenient-to-use formulations.

Investment Considerations

  • Licensed to cultivate and sell medical cannabis as well as cannabinoid oils
  • Canada’s $8.7 billion base domestic retail cannabis market projected to skyrocket
  • Recent agreements to purchase 80 acres enable the addition of three custom-built cultivation facilities, boosting production
  • Anticipated production of 154,000 pounds of cannabis supports revenue projection of $516.2 million per year


Sunday, May 7th, 2017 Featured Stocks Comments Off

ChineseInvestors.com (CIIX)

Founded in 1999, ChineseInvestors.com has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world’s first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer’s disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX’s cannabis-focused “Yelp”-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide.

 


Sunday, May 7th, 2017 Featured Stocks Comments Off